company pharm - this is its production and laboratory in the moscow technopark acquired license for alafanibd already, together with the developers of the drug, it will conduct the second phase of studying research in oncology - this is mainly the study of foreign drugs, and this year, for obvious reasons, there are fewer and fewer of them, and in this regard, we, as a domestic company, are trying to maintain the level . ah and ah, we are taking more and more innovative developments into our portfolio. this is an innovative molecule, and one of the first in the class, and we have very high hopes for its development and release. including in in some foreign countries, the results of the first phase, they were also greatly inspired, by the way the alphabet purposefully twists the receptor for tumor cells, the absence of strong side effects and the main thing, how it helps to prolong life and from the centers in the city of omsk, and the patient received, and received i think 14 rounds of chemo, a to a. the appointment of lafonibo and e, the duration of therapy with this particular drug was 18

alafanib has been shown to work in patients who have already exhausted standard therapy.t is, essentially. these patients are candidates for hospice. the first results have allowed, e, to initiate a phase ii study where the alphabet will already be studied in patients with previously untreated who have not received. uh, medicinal treatment. this is also stomach cancer, the second indication is ovarian cancer, for which there are also very few drugs and little revolution data for this tumor. we decided to try to use the alphabet and learn it in patients too, who can no longer receive standard care. the russian company pharm - this is its production and laboratory in the moscow technopark has acquired a license for the alphabet and, together with the developers of the drug, will conduct the second phase of studying research in oncology - this is basically the study of foreign drugs, and this year, for obvious reasons, there are fewer of them and less, and in this regard, as a domestic company, we try to maintain the level. ah and ah, we are taking more and more innovative d